NA89
NOTICE OF ACCEPTANCE OF SEC. 8 & 9 - E-MAILED
24/04/2024
Voltar para busca
Dado oficial do USPTO
MOFFITT CANCER CENTER
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Snapshot rápido
MOFFITT CANCER CENTER
ST13
US500000086214921Classe
16, 41, 42, 44
Pedido
86214921
Registro
4640131
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
27
Atualização mais recente
24/04/2024
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
16, 41, 42, 44
Data de depósito
07/03/2014
Data de registro
18/11/2014
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
24/04/2024
Última transação
24/04/2024
Escritório responsável
United States Patent and Trademark Office
Código da situação
800
Cadastro oficial
Principal Register
Primeiro uso
30/11/2007
Primeiro uso no comércio
30/11/2007
Código do desenho
4
Tipo de titular
03
Localização do titular
Tampa, FL, US
Examinador
KERTGATE, AMY L
Unidade examinadora
M40
Localização atual
GENERIC WEB UPDATE
Titulares e representantes
Titulares
H. Lee Moffitt Cancer Center and Research Institute, Inc.
Representantes
Corey K. Cho SALIWANCHIK, LLOYD & EISENSCHENK, P.A.
Classificação técnica
Classes Nice
Classe 16Classe 41Classe 42Classe 44
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 16
Publicationsprinted instructional and teaching materialsbrochurespamphletsbulletinsnewsletters and magazinesall in the field of health carecancer protectionpreventiondetection and treatmentmedical diagnostics and prognostics and the evaluation and testing of drug and treatment effectiveness relating to cancer and other diseases
Classe 41
Medical educational servicesconducting lecturesseminars and workshops to health care practitionerspatients and patient caregivers in the field of health carecancer care and prevention of cancermedical diagnosticsprognostics and the evaluation of drug and treatment effectiveness relating to cancer and other diseases
Classe 42
Providing an online database and depository for the collection of clinical and molecular data derived from a patient that is accessible by physicianspatients and researchersan online database in the field of human clinical and molecular data accumulation and analysis for aiding medical diagnosticsprognostics and the evaluation and testing of drug and treatment effectiveness relating to cancer and other diseases for research purposes; medical and clinical research resources in the field of cancer and other diseasesproviding data regarding tumor-specific molecular signatures and the effectiveness of a drug and/or diagnostic test for research purposes; medical and clinical research resources in the field of cancer and other diseasesproviding evidence-based treatment protocols by effectively comparing standard treatment therapies with clinical outcomes for research purposes; medical research services consisting of collection and analysis of data in the field of human clinical and molecular data for aiding medical diagnosticsprognostics and the evaluation and testing of drug and treatment effectiveness relating to cancer and other diseasesmatching particular patients to a particular drugtreatmenttherapy or clinical trial by the specific molecular signature of the patient; collection and analysis of data services in the field of human clinical and molecular data accumulation and analysis for research assistance for medical diagnosticsprognostics and the evaluation and testing of drug and treatment effectiveness relating to cancer and other diseasesproviding objective data in usable form on the effectiveness of a drug or diagnostic test
Classe 44
Providing health caremedical information and counseling in the field of cancer; providing medical screening and diagnostic services with use of patient scanning equipment; providing an online computer database featuring medical information in the field of human clinical and molecular data accumulation and analysis for aiding medical diagnosticsprognostics and the evaluation and testing of drug and treatment effectiveness; medical servicescancer care and prevention of cancermedical diagnosticsprognostics and evaluation of drug and treatment effectiveness relating to cancer and other diseases; medical counseling; telephone hot line counselingoffering advice regarding cancer preventiondetectiontreatment and clinical testing in the field of cancer and other diseases
Publicações
Histórico de despachos e eventos da marca no USPTO.
27 publicações encontradas
RNL1
REGISTERED AND RENEWED (FIRST RENEWAL - 10 YRS)
24/04/2024
89AG
REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED
24/04/2024
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
24/04/2024
E89R
TEAS SECTION 8 & 9 RECEIVED
22/12/2023
REM2
COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED
18/11/2023
NA85
NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
28/03/2020
C15A
REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
28/03/2020
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
28/03/2020
E815
TEAS SECTION 8 & 15 RECEIVED
31/01/2020
REM1
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
18/11/2019
R.PR
REGISTERED-PRINCIPAL REGISTER
18/11/2014
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
02/09/2014
PUBO
PUBLISHED FOR OPPOSITION
02/09/2014
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
13/08/2014
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
26/07/2014
ALIE
ASSIGNED TO LIE
26/07/2014
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
15/07/2014
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
14/07/2014
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
14/07/2014
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
14/07/2014
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
21/06/2014
GNRT
NON-FINAL ACTION E-MAILED
21/06/2014
CNRT
NON-FINAL ACTION WRITTEN
21/06/2014
DOCK
ASSIGNED TO EXAMINER
12/06/2014
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
21/03/2014
NWAP
NEW APPLICATION ENTERED
11/03/2014
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace MOFFITT CANCER CENTER ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.